In-depth Analysis

    CLINICAL SHEET
    Bone Marrow Aspirate Concentrate (BMAC) in:

    MODERATE-SEVERE OSTEOARTHRITIS

    Treatment description
    Autologous bone marrow concentrate (Bone Marrow Aspirate Concentrate – BMAC), obtained through aspiration and subsequent concentration of bone marrow, is a rich source of mesenchymal stromal cells (MSCs), growth factors, bioactive cytokines, and immunomodulatory molecules. The treatment consists of injection of the BMAC suspension directly into the site of the non-union, aiming to promote bone regeneration and consolidation.

    Biological and pathophysiological effects
    → Promotion of bone regeneration through the release of growth factors such as BMP, PDGF, TGF-β, and VEGF.
    → Paracrine action of MSCs in enhancing angiogenesis and synthesis of the bone extracellular matrix.
    → Modulation of the local inflammatory response with reduction of pro-inflammatory cytokines and attenuation of the pathological microenvironment.
    → Stimulation of osteogenic differentiation and increased formation of mature bone tissue.

    Specific clinical indications
    → Non-union of long bones (e.g., femur, tibia, humerus) refractory to surgical or conservative treatments.
    → Delayed bone consolidation with poor response to traditional therapies.
    → Patients with risk factors for non-union requiring additional biological support.

    Documented clinical benefits
    → Acceleration of bone consolidation times and improvement in the quality of the bone callus.
    → Reduction of pain and improvement of post-treatment motor function.
    → Lower risk of complications compared to invasive surgical treatments.
    → Potential decrease in the need for surgical revisions or traditional bone grafts.

    Conclusions
    The use of bone marrow concentrate in non-unions represents an innovative and safe biological strategy capable of effectively stimulating bone regeneration and promoting healing in resistant non-union cases, contributing to improved clinical and functional outcomes for patients.

    PSEUDOARTHROSIS

    Treatment Description

    Autologous Bone Marrow Aspirate Concentrate (BMAC) is a natural source of mesenchymal stem cells (MSCs), bioactive cytokines, growth factors, and immunomodulatory molecules. The treatment involves ultrasound-guided injection of the concentrate into the pathological tendon site.

    Biological and Pathophysiological Effects

    → Stimulation of tendon tissue regeneration via growth factor release (PDGF, TGF-β, VEGF).
    → Paracrine MSC signaling promoting angiogenesis and extracellular matrix synthesis.
    → Modulation of chronic inflammation with reduction of pro-inflammatory cytokines.
    → Local antifibrotic and analgesic effects.

    Specific Clinical Indications

    → Chronic tendinopathies unresponsive to conservative treatments (e.g., Achilles, patellar tendinopathy, lateral epicondylitis).
    → Active patients or athletes with degenerative tendon lesions.
    → Failed PRP or corticosteroid injections.

    Documented Clinical Benefits

    → Tendon structure improvement
    → Pain reduction and improved functional scores (VAS, VISA-A/P).
    → Low complication rate and high safety profile.
    → Potential reduction in recovery time in high-performance athletes.

    Conclusions

    BMAC therapy offers an innovative biological strategy for resistant tendinopathies, promoting tissue repair and improving function in patients unresponsive to traditional treatments.

    COMPLEX FRACTURE

    Treatment description
    BMAC can be used as a biological adjunct in complex fractures, either via percutaneous injection or intraoperatively, to promote bone healing in cases at risk of delayed union or non-union.

    Biological and pathophysiological effects
    → Enhancement of bone regeneration through osteoprogenitor cells.
    → Increased synthesis of bone matrix.
    → Reduction of local post-fracture inflammation.
    → Activation of the osteogenic microenvironment.

    Specific clinical indications
    → Articular, comminuted, or secondarily unstable fractures.
    → Adjunct treatment in complex osteosynthesis.
    → Patients at risk of delayed healing (e.g., osteoporosis, comorbidities).

    Documented clinical benefits
    → Shorter bone healing time.
    → Improved quality of radiographically visible callus.
    → Reduced need for reintervention or bone grafting.

    Conclusions
    The use of BMAC represents a valuable resource in the management of complex fractures, supporting improved bone repair and reducing the risk of non-union or delayed healing.

    UNCEMENTED PROSTHESIS IMPLANTATION

    Treatment description
    BMAC is locally applied during the implantation of uncemented prostheses to promote
    osteointegration, leveraging osteoprogenitor cells and osteoinductive factors.

    Biological and physiopathological effects
    → Enhances osteogenesis around the implant.
    → Promotes local angiogenesis for vascular support.
    → Shortens osteointegration time.
    → Improves secondary implant stability.

    Specific clinical indications
    → Primary uncemented arthroplasty in patients at risk of poor bone ingrowth.
    → Revision surgeries with marginal bone loss.
    → Localized osteopenia or osteoporosis.

    Documented clinical benefits
    → Improved bone-implant integration.
    → Reduced early loosening.
    → Favorable safety profile without increased infection risk.

    Conclusions
    Intraoperative BMAC use in uncemented prosthesis implantation supports bone healing, reduces early complications, and enhances long-term stability and outcomes.

    HIP PROSTHESIS REVISION

    Treatment description
    In the context of hip prosthesis revisions, BMAC is locally applied to acetabular or femoral bone defects, often in combination with bone substitutes (allografts or synthetic scaffolds), with the goal of stimulating osteointegration, promoting bone regeneration, and enhancing implant stability.

    Biological and physiopathological effects
    → Promotion of bone regeneration via the release of osteoinductive factors (BMPs, TGF-β, PDGF, VEGF).
    → Increased osteoblastic activity through MSC differentiation into osteoprogenitor cells.
    → Immunomodulatory action and reduction of local inflammation, creating a pro-regenerative microenvironment.
    → Angiogenic support for neovascularization of the graft or bone substitute.
    → Enhanced osteointegration of the implant by activating biological bone healing mechanisms.

    Specific clinical indications
    → Acetabular contained or segmental bone defects (Paprosky IIB–IIIB) during prosthesis revision.
    → Metaphyseal or diaphyseal femoral bone defects in femoral stem reimplantation (Paprosky II–IV).
    → Patients with impaired bone regenerative capacity (e.g., osteoporosis, post-infectious damage, multiple prior revisions).
    → Need to enhance biological support for cementless implants or implants mounted on bone grafts.

    Documented clinical benefits
    → Promotes implant and graft osteointegration, reducing the risk of secondary failure.
    → Improves defect filling and bone regeneration, providing better mid-term implant stability.
    → Potentially reduces the need for massive structural grafts or banked bone grafts.
    → Enhances the quality of newly formed bone, with radiographic and clinical improvements.
    → Improves joint function and reduces postoperative pain.

    Conclusions
    The use of autologous bone marrow aspirate concentrate (BMAC) is a safe and advanced therapeutic option for complex hip prosthesis revisions, particularly in the presence of acetabular or femoral bone defects. The combination of BMAC with scaffolds or allografts enhances bone regeneration, promotes implant osteointegration, and improves long-term functional outcomes, while reducing the risk of reoperation and biological complications.